Clinical Nuclear Medicine

Skip Navigation LinksHome > September 2013 - Volume 38 - Issue 9 > Metastatic Prostate Cancer Proven by 18F-FCH PET/CT Staging...
Clinical Nuclear Medicine:
doi: 10.1097/RLU.0b013e31829b9d6b
Interesting Images

Metastatic Prostate Cancer Proven by 18F-FCH PET/CT Staging Scan in Patient With Normal PSA but High PSA Doubling Time

Hodolič, Marina MD*; Maffione, Anna Margherita MD; Fettich, Jure MD*; Gubina, Borut MD; Cimitan, Marino MD§; Rubello, Domenico MD

Collapse Box


Abstract: A 59-year-old man presented with frequent urination. Six months ago, his prostate-specific antigen (PSA) was 1.56 ng/mL; currently it is 3.5 ng/mL (PSA doubling time = 6 months; PSA velocity = 0.19 ng/mL/mo). Biopsy revealed aggressive prostate cancer (Gleason score 5 + 5). Staging with 18F-fluorocholine PET/CT (18F-FCH PET/CT) demonstrated lymph node metastasis. After 6 months of hormonal therapy with goserelin, PSA decreased to 0.38 ng/mL. A 18F-FCH PET/CT restaging scan demonstrated a global reduction of 18F-FCH lesion uptake with disappearance of some mediastinal and iliac pelvic lymph node activity.

© 2013 by Lippincott Williams & Wilkins


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.